Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts

Vaccine

Volumn 32, Issue 17, 2014, Pages 1946-1953

  Haralambieva, Iana H ^a   Salk, Hannah M ^a   Lambert, Nathaniel D ^a   Ovsyannikova, Inna G ^a   Kennedy, Richard B ^a   Warner, Nathaniel D ^a   Pankratz, V Shane ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibodies; Cellular immunity; Ethnicity; MMR; Race; Rubella vaccine; Sex

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 6; MEASLES MUMPS RUBELLA VACCINE; NEUTRALIZING ANTIBODY; RUBELLA VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; COHORT ANALYSIS; CYTOKINE PRODUCTION; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HISPANIC; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RUBELLA; SCHOOL CHILD; SEX DIFFERENCE; VACCINATION;

ANTIBODIES; CELLULAR IMMUNITY; ETHNICITY; MMR; RACE; RUBELLA VACCINE; SEX;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNITY, HUMORAL; INTERFERON-GAMMA; INTERLEUKIN-6; LINEAR MODELS; MALE; RUBELLA; RUBELLA VACCINE; YOUNG ADULT;

EID: 84896319594     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.090     Document Type: Article

References (53)

1. Poland G.A., Ovsyannikova I.G., Kennedy R.B., Haralambieva I.H., Jacobson R.M. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. Omics 2011, 15(9):625-636.
2. Klein S.L., Jedlicka A., Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010, 10(5):338-349.
3. Haralambieva I.H., Ovsyannikova I.G., Pankratz V.S., Kennedy R.B., Jacobson R.M., Poland G.A. The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches. Exp Rev Vaccines 2013, 12(1):57-70.
4. Umlauf B.J., Haralambieva I.H., Ovsyannikova I.G., Kennedy R.B., Pankratz V.S., Jacobson R.M., et al. Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination. Viral Immunol 2012 Feb, 25(1):29-36.
5. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., Poland G.A. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol 2004, 65:1506-1515.
6. Haralambieva I.H., Ovsyannikova I.G., Kennedy R.B., Larrabee B.R., Shane Pankratz V., Poland G.A. Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals. Hum Immunol 2013, 74(10):1263-1266.
7. Poland G.A., Grabenstein J.D., Neff J.M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005, 23(17-18):2078-2081.
8. McQuillan G.M., Kruszon-Moran D., Hyde T.B., Forghani B., Bellini W., Dayan G.H. Seroprevalence of measles antibody in the US population, 1999-2004. J Infect Dis 2007, 196(10):1459-1464.
9. Gardner E.M., Gonzalez E.W., Nogusa S., Murasko D.M. Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population. Vaccine 2006, 24(10):1609-1614.
10. Poland G.A., Jacobson R.M., Colbourne S.A., Thampy A.M., Lipsky J.J., Wollan P.C., et al. Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 1999, 17:1525-1531.
11. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., Poland G.A. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J Infect Dis 2005, 191(4):515-519.
12. Ovsyannikova I.G., Jacobson R.M., Dhiman N., Vierkant R.A., Pankratz V.S., Poland G.A. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. Pediatrics 2008, 121(5):e1091-e1099.
13. de la C.S., Kouri G., Guzman M.G. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 2007, 152(3):533-542.
14. Stead W.W., Senner J.W., Reddick W.T., Lofgren J.P. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 1990, 322(7):422-427.
15. Hemmige V., McFadden R., Cook S., Tang H., Schneider J.A. HIV prevention interventions to reduce racial disparities in the United States: a systematic review. J Gen Int Med 2012, 27(8):1047-1067.
16. Haralambieva I.H., Dhiman N., Ovsyannikova I.G., Vierkant R.A., Pankratz V.S., Jacobson R.M., et al. 2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Hum Immunol 2010, 71(4):383-391.
17. Ovsyannikova I.G., Haralambieva I.H., Dhiman N., O'Byrne M.M., Pankratz V.S., Jacobson R.M., et al. Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis 2010, 201(2):207-213.
18. Ovsyannikova I.G., Dhiman N., Haralambieva I.H., Vierkant R.A., O'Byrne M.M., Jacobson R.M., et al. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum Genet 2010, 127:207-221.
19. Dhiman N., Haralambieva I.H., Kennedy R.B., Vierkant R.A., O'Byrne M.M., Ovsyannikova I.G., et al. Assessment of SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccination. Immunogenetics 2010, 62(4):197-210.
20. Dhiman N., Haralambieva I.H., Vierkant R.A., Pankratz V.S., Ryan E., Jacobson R.M., et al. Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in health vaccines. Cytokine 2010, 50:24-29.
21. Kennedy R.B., Ovsyannikova I.G., Pankratz V.S., Haralambieva I.H., Vierkant R.A., Jacobson R.M., et al. Genome-wide genetic associations with IFNgamma response to smallpox vaccine. Hum Genet 2012, 131(9):1433-1451.
22. Haralambieva I.H., Ovsyannikova I.G., Dhiman N., Kennedy R.B., O'Byrne M., Pankrantz V.S., et al. Common SNPs/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African-Americans. J Infect Dis 2011, 204(3):433-441.
23. Ovsyannikova I.G., Haralambieva I.H., Kennedy R.B., Pankratz V.S., Vierkant R.A., Jacobson R.M., et al. Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination. Gene 2012, 510:59-65.
24. Lambert N.D., Haralambieva I.H., Ovsyannikova I.G., Larrabee B.R., Pankratz V.S., Poland G.A. Characterization of humoral and cellular immunity to rubella vaccine in four distinct cohorts. Immunol Res 2013, 58(1):1-8.
25. Kennedy R.B., Ovsyannikova I.G., Pankratz V.S., Vierkant R.A., Jacobson R.M., Ryan M.A., et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009, 27(25-26):3319-3323.
26. Lambert N.D., Pankratz V.S., Larrabee B.R., Ogee-Nwankwo A., Chen M.H., Icenogle J.P., et al. High-throughput assay optimization and statistical interpolation of rubella-specific neutralizing antibody titers. Clin Vacc Immunol 2014, [epub ahead of print].
27. Ovsyannikova I.G., Haralambieva I.H., Vierkant R.A., O'Byrne M.M., Jacobson R.M., Poland G.A. The association of CD46, SLAM, and CD209 cellular receptor gene snps with variations in measles vaccine-induced immune responses-a replication study and examination of novel polymorphisms. Hum Hered 2011, 72(3):206-223.
28. Haralambieva I.H., Oberg A.L., Dhiman N., Ovsyannikova I.G., Kennedy R.B., Grill D.E., et al. High-dimensional gene expression profiling studies in high and low responders to primary smallpox vaccination. J Infect Dis 2012, 206(10):1512-1520.
29. Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006, 38(8):904-909.
30. Pritchard J.K., Stephens M., Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000, 155(2):945-959.
31. Haralambieva I.H., Ovsyannikova I.G., Umlauf B.J., Vierkant R.A., Pankratz S.V., Jacobson R.M., et al. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine 2011, 29(48):8988-8997.
32. Haralambieva I.H., Ovsyannikova I.G., Kennedy R.B., Vierkant R.A., Pankratz S.V., Jacobson R.M., et al. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 2011, 29(45):7883-7895.
33. Haralambieva I.H., Ovsyannikova I.G., O'Byrne M., Pankratz V.S., Jacobson R.M., Poland G.A. A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine 2011, 29(27):4485-4491.
34. Shackelford P.G., Granoff D.M., Nahm M.H., Scott M.G., Suarez B., Pandey J.P., et al. Relation of age, race, and allotype to immunoglobulin subclass concentrations. Pediat Res 1985 Aug, 19(8):846-849.
35. Maddison S.E., Stewart C.C., Farshy C.E., Reimer C.B. The relationship of race, sex, and age to concentrations of serum immunoglobulins expressed in international units in healthy adults in the USA. Bull World Health Org 1975, 52(2):179-185.
36. Montefiori D.C., Metch B., McElrath M.J., Self S., Weinhold K.J., Corey L. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis 2004, 190(11):1962-1969.
37. Christy C., Pichichero M.E., Reed G.F., Decker M.D., Anderson E.L., Rennels M.B., et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics 1995, 96(Suppl 2):584-587.
38. Monath T.P., Nichols R., archambault W.T., Moore L., Marchesani R., Tian J., et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J TropMed Hyg 2002, 66(5):533-541.
39. Guthridge S., McIntyre P., Isaacs D., Hanlon M., Patel M. Differing serologic responses to an haemophilus influenzae type b polysaccharide-neisseria meningitidis outer membrane protein conjugate (PRP-OMPC) vaccine in australian aboriginal and caucasian infants-implications for disease epidemiology. Vaccine 2000 May 22, 18(23):2584-2591.
40. Greenberg D.P., Vadheim C.M., Partridge S., Chang S.J., Chiu C.Y., Ward J.I. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. The Kaiser-UCLA Vaccine Study Group. J Infect Dis 1994, 170(1):76-81.
41. Siber G.R., Santosham M., Reid G.R., Thompson C., Almeido-Hill J., Morell A., et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med 1990, 323:1387-1392.
42. Van Dyke A.L., Cote M.L., Wenzlaff A.S., Land S., Schwartz A.G. Cytokine SNPs Comparison of allele frequencies by race and implications for future studies. Cytokine 2009, 46(2):236-244.
43. Pajewski N.M., Parker S.D., Poland G.A., Ovsyannikova I.G., Song W., Zhang K., et al. The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed. Genes Immun 2011, 12(6):457-465.
44. Ovsyannikova I.G., Haralambieva I.H., Kennedy R.B., O'Byrne M.M., Pankratz V.S., Poland G.A. Genetic variation in IL18R1 and IL18 genes and inteferon gamma ELISPOT response to smallpox vaccination: an unexpected relationship. J Infect Dis 2013 Nov 1, 208(9):1422-1430.
45. Ovsyannikova I.G., Haralambieva I.H., Vierkant R.A., Pankratz V.S., Poland G.A. The role of polymorphisms in toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum Genet 2011, 130(4):547-561.
46. Mitchell L.A. Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation. J Med Microbiol 1999, 48(12):1075-1080.
47. Dominguez A., Plans P., Costa J., Torner N., Cardenosa N., Batalla J., et al. Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study. EurJ Clin Microbiol Infect Dis 2006, 25(5):310-317.
48. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17(7):1055-1065.
49. LeBaron C.W., Forghani B., Matter L., Reef S.E., Beck C., Bi D., et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009, 200(6):888-899.
50. Davidkin I., Jokinen S., Broman M., Leinikki P., Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008, 197(7):950-956.
51. Davidkin I., Peltola H., Leinikki P., Valle M. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine 2000, 18(27):3106-3112.
52. Rumke H.C., Loch H.P., Hoppenbrouwers K., Vandermeulen C., Malfroot A., Helm K., et al. Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine 2011, 29(22):3842-3849.
53. Nascimento Silva J.R., Camacho L.A., Siqueira M.M., Freire Mde S., Castro Y.P., Maia Mde L., et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011, 29(37):6327-6334.